Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide

Inventors: Jami Kern (Fort Worth, TX); G. Michael Wall (Fort Worth, TX)

Assignee: Nacuity Pharmaceuticals, Inc.

A61K31/16 A61P27/02

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12667548
App. No.: 19/338,634
Granted: Jun 30, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are methods for the treatment of retinitis pigmentosa in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA).

Claims (22)

1 . A method for treating an eye disease caused by oxidative damage in a subject in need thereof, the method comprising:

identifying that the subject has retinitis pigmentosa associated with Usher Syndrome (RP/USH);

providing an effective amount of N-acetylcysteine amide (NACA) sufficient to slow degradation of an Ellipsoid Zone (EZ) area.

2 . The method of claim 1 , wherein the NACA is provided orally, peritoneally, intravenously, dermally, bucally, sublingually, topically, topical ocularly, intraocularly, intravitreally, transmucosally, or by inhalation.

3 . The method of claim 1 , wherein the NACA slows a reduction in the EZ area as measured by Spectral-Domain-Optical Coherence Tomography (SD-OCT).

4 . The method of claim 1 , wherein the NACA is dosed as single or multiple dosage units (including tablets) per day.

5 . The method of claim 1 , wherein the NACA is dosed at 125 mg per day.

6 . The method of claim 1 , wherein the NACA is dosed at 125 mg twice per day.

7 . The method of claim 1 , wherein the NACA is dosed at 125 mg four times per day.

8 . The method of claim 1 , wherein the NACA is dosed greater than 200 mg per day.

9 . The method of claim 1 , wherein the NACA is dosed at 250 mg per day.

10 . The method of claim 1 , wherein the NACA is dosed at 250 mg twice per day.

11 . The method of claim 1 , wherein the NACA is dosed at 500 mg per day.

12 . The method of claim 1 , wherein the NACA is dosed at 750 mg per day.

13 . The method of claim 1 , wherein the NACA is dosed at 1,000 mg per day.

14 . The method of claim 1 , wherein the NACA is dosed at 1,250 mg per day.

15 . The method of claim 1 , wherein the NACA is dosed at 1,500 mg per day.

16 . The method of claim 1 , wherein the NACA is dosed for at least 6 months, 9 months, 12 months, 18 months or 24 months.

17 . The method of claim 1 , wherein the NACA is dosed for less than 6 months.

18 . The method of claim 1 , wherein the NACA is dosed for at least one of 6, 9, 12, 18, or 24 months.

19 . The method of claim 1 , wherein the NACA is dosed for more than 24 months.

20 . The method of claim 1 , wherein the NACA is administered in daily doses of about 0.5, 1, 2, 3, 3.6, 4, 5, 6, 7, 7.14, 7.2, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 75, 80, 90, 100, 110, 120, 125, 130, 140, 150, 160, 170, 175, 180, 190, 200, 210, 220, or 225 mg/Kg.